Toni Choueiri

, Director of the Lank Center for Genitourinary Oncology · Mass General Brigham

Credentials: · · · ·

History

Optimizing Neoadjuvant/Adjuvant Anti-PD-1 Therapy for Localized Renal Cell Carcinoma
National Cancer Institute · R01
PI · $740K · Brigham and Women's Hospital
2026–2031
Assessment of Germline Variants Associated with Immune-Related Adverse Events Following Immune Checkpoint Inhibitors
National Cancer Institute · R01
Contact PI · $3.5M · Dana-Farber Cancer Inst
2024–2029
Tissue-Based Biomarkers of Anti-PD-1-Based Therapy in Metastatic Renal Cell Carcinoma
National Cancer Institute · R01
Contact PI · $3.6M · Dana-Farber Cancer Inst
2022–2027
Dana-Farber/Harvard Cancer Center
National Cancer Institute · P30
Project lead · $150.2K · Dana-Farber Cancer Inst
1997–2026

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
Principal investigator · Active not recruiting · Phase 3
AstraZeneca
2021–2027
ABEMA Alone or in COMBO With MK-6482
Principal investigator · Completed · Phase 1
Dana-Farber Cancer Institute
2020–2024
NeoVax Plus Ipilimumab in Renal Cell Carcinoma
Principal investigator · Active not recruiting · Phase 1
Patrick Ott, MD, PhD
2019–2030
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Principal investigator · Active not recruiting · Phase 2
Toni Choueiri, MD
2017–2026